RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 66 filers reported holding RA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $100,525,000 | +2.3% | 2,093,839 | 0.0% | 0.62% | +18.6% |
| Q4 2019 | $98,264,000 | +77.1% | 2,093,839 | -10.7% | 0.52% | +38.5% |
| Q3 2019 | $55,471,000 | +2.4% | 2,345,496 | +30.2% | 0.38% | +2.4% |
| Q2 2019 | $54,177,000 | +193.8% | 1,801,695 | +118.9% | 0.37% | +211.9% |
| Q1 2019 | $18,438,000 | +23.1% | 823,113 | 0.0% | 0.12% | -4.1% |
| Q4 2018 | $14,981,000 | +365.4% | 823,113 | +362.5% | 0.12% | +485.7% |
| Q3 2018 | $3,219,000 | +81.8% | 177,952 | 0.0% | 0.02% | +61.5% |
| Q2 2018 | $1,771,000 | +87.4% | 177,952 | 0.0% | 0.01% | +62.5% |
| Q1 2018 | $945,000 | -37.5% | 177,952 | 0.0% | 0.01% | -38.5% |
| Q4 2017 | $1,513,000 | -41.8% | 177,952 | 0.0% | 0.01% | -38.1% |
| Q3 2017 | $2,598,000 | -22.1% | 177,952 | 0.0% | 0.02% | -27.6% |
| Q2 2017 | $3,335,000 | -12.0% | 177,952 | 0.0% | 0.03% | -6.5% |
| Q1 2017 | $3,789,000 | +40.2% | 177,952 | 0.0% | 0.03% | +19.2% |
| Q4 2016 | $2,703,000 | – | 177,952 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |